From ancient immunity to disruptive cure

We harness the immense diversity of microbial antiphage defense into revolutionary technologies and therapeutics

About

Founded in 2017 and based in Israel, Pantheon Biosciences is an early-stage biotechnology company committed to harnessing the immense diversity of bacterial immunity into revolutionary biomedical platforms and therapeutics. We are leveraging unexploited insights hidden in bacterial defense systems to develop innovative antiviral drugs and next-generation therapeutics for molecular engineering. Driven by cutting-edge research from Prof. Rotem Sorek of The Weizmann Institute of Science, we develop Pantheon’s proprietary novel antiviral small molecules, creating a broad product portfolio derived from the novel bacterial defense systems.

Founded in 2017 and based in Israel, Pantheon Biosciences is an early-stage biotechnology company committed to harnessing the immense diversity of bacterial immunity into revolutionary biomedical platforms and therapeutics. We are leveraging unexploited insights hidden in bacterial defense systems to develop innovative antiviral drugs and next-generation therapeutics for molecular engineering. Driven by cutting-edge research from Prof. Rotem Sorek of The Weizmann Institute of Science, we develop Pantheon’s proprietary novel antiviral small molecules, creating a broad product portfolio derived from the novel bacterial defense systems.

Founded in 2017 and based in Israel, Pantheon Biosciences is an early-stage biotechnology company committed to harnessing the immense diversity of bacterial immunity into revolutionary biomedical platforms and therapeutics. We are leveraging unexploited insights hidden in bacterial defense systems to develop innovative antiviral drugs and next-generation therapeutics for molecular engineering. Driven by cutting-edge research from Prof. Rotem Sorek of The Weizmann Institute of Science, we develop Pantheon’s proprietary novel antiviral small molecules, creating a broad product portfolio derived from the novel bacterial defense systems.

Science

The Sorek lab at Weizmann Institute of Science has developed revolutionary technology for systematic discovery of new immune systems. This technology involves massive computational predictions followed by experimental validation.

Computational

Experimental

Programs

The natural nucleoside analogs in development by Pantheon, intend to bring innovation to a validated class of antiviral therapeutics and to address acute unmet needs. Pantheon is deciphering multiple bacterial defense systems aiming to uncover novel biological machineries and to develop disruptive technologies and products.

Our Team

World leading scientist in CRISPR research and microbial genomics.Inventor of over 40 patents, 9 of which licensed to biotech companies. Scientific founder of 3 biotech companies, including BiomX (NSYE:PHGE). Elected member of the American Academy of Microbiology and EMBO. Cutting edge publications portfolio in Nature (2012,2015,2017,2018, 2019) and Science (2014, 2015, 2016, 2017, 2018, 2019)

Professor Rotem Sorek

Scientific Founder

14 years of industrial and academic experience in multidisciplinary research and development of novel drugs in immuno-oncology. Led multiple programs from inception to various stages of pre-clinical and early clinical development. Before joining Pantheon Bioscience Arthur served as a principal investigator at Hadassah Medical Center and for the past four years was the Head of Immuno-Oncology Research at Compugen (NSYE:CGEN)

Arthur Machlenkin, PhD

CEO

Lianet Noda, PhD

Associate Director, Protein Biochemistry

Helena Shomar, PhD

Scientist

Masha Rosenberg, PhD

Scientist

Nir Tal, PhD

Scientist

Erez Eliyahu, PhD

Scientist

Tamar Shalev

Office Manager

Contact

Pantheon Biosciences

Kishon 18, Yavne 8122004, Israel

ALL RIGHTS RESERVED PANTHEON BIOSCIENCES, 2020 | site design by yuvaldesign.com